Growth Hormone AxisIn StockGrowth Hormone Axis
CJC-1295 With DAC
Also known as: DAC:GRF, CJC-1295 DAC
CJC-1295 variant conjugated with a Drug Affinity Complex for sustained GHRH-receptor activation research.
CJC-1295 with DAC is the long-acting form of the CJC-1295 GHRH analog, featuring a maleimidopropionic-acid lysine linker that enables reversible covalent binding to serum albumin.
This extends the effective half-life from minutes (no-DAC form) to days (DAC form) in vivo.The DAC variant has been used in research settings where sustained GHRHR signaling is required to study tonic-activation biology, as opposed to the pulsatile-activation research supported by the no-DAC variant.
Published work has examined downstream effects on IGF-1 levels and GH-axis dynamics in animal models.Because of the albumin-binding linker chemistry, CJC-1295 (DAC) is somewhat more expensive to synthesize than the no-DAC form and is cataloged at a modest premium.
Research applications
- Sustained-activation GHRHR pharmacology
- Albumin-binding drug-design research
- IGF-1 axis response studies in animal models
- Comparative pharmacokinetic research (DAC vs. no-DAC)
- Long-acting peptide formulation research
Technical profile
- Net content
- 10 mg
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3648.4g/mol
- CAS
- 863288-34-0
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
CJC-1295 with Drug Affinity Complex is a GHRH analogue modified with a maleimidopropionic acid linker that binds serum albumin. The DAC extension prolongs its half-life to approximately 6-8 days, enabling sustained growth hormone elevation.
